1. 1 Huang L, Zhang R, Hu Y, Zhou H, Cao J, Lv H, et al. Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017. Antimicrob Resist Infect Control. 2019; 8: 1-9. DOI: 10.1186/s13756-019-0539-x [
DOI:10.1186/s13756-019-0539-x] [
PMID] [
]
2. 2 Mohamadi S, Rezaee R, Hashemi M, Kiani B, Ghasemi S, Alizadeh Sani M, et al. Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Staphylococcus aureus (VRSA), and Vancomycin-Resistant Enterococci (VRE) Contamination of Food Samples in Iran: A Systematic Review and Meta-Analysis.Iran J Med Microbiol. 2023; 17(2): 135-49. DOI: 10.30699/ijmm.17.2.135 [
DOI:10.30699/ijmm.17.2.135]
3. 3 Wang Y, Oppong TB, Liang X, Duan G, Yang H. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization in patients: A meta-analysis. Am J Infect Control.. 2020; 48(8): 925-32. DOI: 10.1016/j.ajic.2019.11.010 [
DOI:10.1016/j.ajic.2019.11.010] [
PMID]
4. 4 Mousavi S, Zargarzadeh A. Rational Drug Use in Iran: A Call for Action. J Pharm Care. 2015; 2(2): 47-8. URL: https://jpc.tums.ac.ir/index.php/jpc/article/view/44
5. 5 Basaran NF, Akici A. Patients' experience and perspectives on the rational use of drugs in Turkey: a survey study. Patient Prefer Adherence. 2012: 719-24. DOI: 10.2147/PPA.S34922 [
DOI:10.2147/PPA.S34922] [
PMID] [
]
6. 6 Blomberg M, Jensen MB, Henry A, Singh S, Banipal RS, da Cunha-Bang C, et al. Antimicrobial drug use in a small Indian community hospital. Trop Doct. 2010; 40(4): 194-8. DOI: 10.1258/td.2010.090157 [
DOI:10.1258/td.2010.090157] [
PMID]
7. 7 Lavigne J-P, Bruyère F, Bernard L, Combescure C, Ronco E, Lanotte P, et al. Resistance and virulence potential of uropathogenic Escherichia coli strains isolated from patients hospitalized in urology departments: a French prospective multicentre study. J Med Microbiol. 2016; 65(6): 530-7. DOI: 10.1099/jmm.0.000247 [
DOI:10.1099/jmm.0.000247] [
PMID]
8. 8 La Fauci V, Alessi V. Antibiotic resistance: Where are we going? Ann Ig. 2018; 30(4): 52-7. DOI: 10.7416/ai.2018.2235
9. 9 Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al‐Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, et al. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. J Clin Lab Anal. 2022; 36(9): e24655. DOI: 10.1002/jcla.24655 [
DOI:10.1002/jcla.24655] [
PMID] [
]
10. 10 Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. J Infect Public Health. 2021; 14(12): 1750-66. DOI: 10.1016/j.jiph.2021.10.020 [
DOI:10.1016/j.jiph.2021.10.020] [
PMID]
11. 11 Tamadon MR, Soliemani A, Yarmohamadi M, Semnani V, Ghorbani R, Malek F, et al. Similar efficacy of vancomycin and teicoplanin in treatment of catheter related infection in hemodialysis patients. koomesh. 2012;14(1):e152546. URL: https://brieflands.com/articles/koomesh-152546
12. 12 Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020; 55(4): 105944. DOI: 10.1016/j.ijantimicag.2020.105944 [
DOI:10.1016/j.ijantimicag.2020.105944] [
PMID] [
]
13. 13 Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving.BMJ. 1995; 310(6987): 1122-6. DOI: 10.1136/bmj.310.6987.1122 [
DOI:10.1136/bmj.310.6987.1122] [
PMID] [
]
14. 14 Elseviers M, Wettermark B, Mueller T, Benko R, Bennie M, Gvozdanovic K, et al. Drug utilization research: methods and applications: John Wiley & Sons; 2nd Edition. 2024. ISBN: 978-1-119-91165-4 [
DOI:10.1002/9781119911685.ch1]
15. 15 Wettermark B, Elseviers M, Mueller T, Almarsdottir A, Benkő R, Bennie M, et al. Introduction to drug utilization research. Drug utilization research: methods and applications. 2024: 1-12. DOI:10.1002/9781118949740.ch1 [
DOI:10.1002/9781118949740.ch1]
16. 16 Sacha GL, Neuner EA, Athans V, Bass SN, Pallotta A, Rivard KR, et al. Retrospective evaluation of the use of ceftolozane/tazobactam at a large academic medical center. What Did We Learn?. Infect Dis Clin Pract (Baltim Md). 2017; 25(6): 305-9. DOI: 10.1097/IPC.0000000000000553. URL: https://journals.lww.com/infectdis/abstract/2017/11000/retrospective_evaluation_of_the_use_of.5.aspx [
DOI:10.1097/IPC.0000000000000553]
17. 17 Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother. 2006; 12(4): 185-9. DOI: 10.1007/s10156-006-0446-y [
DOI:10.1007/s10156-006-0446-Y] [
PMID]
18. 18 Hajialigol M, Farsaei S, Shirani K. Prospective Study of Irrational Prescription of Teicoplanin in a Large Academic Hospital: A Dilemma of Antimicrobial Resistance. J Res Pharm Pract. 2020; 9(1): 50-5. DOI: 10.4103/jrpp.JRPP_19_104 [
DOI:10.4103/jrpp.JRPP_19_104] [
PMID] [
]
19. 19 Farsad BF, Hadavand N, Salehi H, Shekari F. Carbapenems, Linezolid, Teicoplanin utilization evaluation in a large teaching based hospital (Shahid Rajaie heart center, Tehran): a quality improvement study. Biomed Pharmacol J. 2016; 9(2): 525-32. DOI: https://dx.doi.org/10.13005/bpj/968 [
DOI:10.13005/bpj/968]
20. 20 Kaur J, Mir T, Dixit P, Uddin M, Kadari S, Lee Y, et al. The Use of Vancomycin Versus Teicoplanin in Treating Febrile Neutropenia: A Meta-Analysis and Systematic Review. Cureus. 2021; 13(5): e15269. DOI: 10.7759/cureus.15269 [
DOI:10.7759/cureus.15269]
21. 21 Lee JH, Choi MG, Park HJ, Kim HC, Choi C-M. Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. BMC Infect Dis. 2022; 22(1): 600. DOI: 10.1186/s12879-022-07549-2 [
DOI:10.1186/s12879-022-07549-2] [
PMID] [
]
22. 22 Sanford JP. The Sanford guide to antimicrobial therapy: Antimicrobial Therapy; 2007.
23. 23 Kayambankadzanja RK, Lihaka M, Barratt-Due A, Kachingwe M, Kumwenda W, Lester R, et al. The use of antibiotics in the intensive care unit of a tertiary hospital in Malawi. BMC Infect Dis. 2020; 20(1): 776. DOI: 10.1186/s12879-020-05505-6. [
DOI:10.1186/s12879-020-05505-6] [
PMID] [
]